KR880004312A - 특정 표적 세포의 검출 및 치사용 친화력 증강 면역학적 시약 - Google Patents

특정 표적 세포의 검출 및 치사용 친화력 증강 면역학적 시약 Download PDF

Info

Publication number
KR880004312A
KR880004312A KR1019870010382A KR870010382A KR880004312A KR 880004312 A KR880004312 A KR 880004312A KR 1019870010382 A KR1019870010382 A KR 1019870010382A KR 870010382 A KR870010382 A KR 870010382A KR 880004312 A KR880004312 A KR 880004312A
Authority
KR
South Korea
Prior art keywords
reagent
reagents
hapten
antigen
synthetic molecule
Prior art date
Application number
KR1019870010382A
Other languages
English (en)
Other versions
KR900005622B1 (ko
Inventor
바르베 자끄
델라그 미셀
르 두쌀 쟝-마르끄
두쌀 쟝-마르끄르
Original Assignee
임뮤노테크
앙뜨완느 바레
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 임뮤노테크, 앙뜨완느 바레 filed Critical 임뮤노테크
Publication of KR880004312A publication Critical patent/KR880004312A/ko
Application granted granted Critical
Publication of KR900005622B1 publication Critical patent/KR900005622B1/ko

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Optics & Photonics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

내용 없음

Description

특정 표적 세포의 검출 및 치사용 친화력 증강 면역학적 시약
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (42)

  1. a) 적합한 합텐에 대하여 결합 친화력을 가진 모노클로날 항체 또는 소편에 접합된 적합한 항원에 대하여 결합 친화력을 가진 모노클로날 항체 또는 소편, b) 제1a)항이 접합체에 대하여 결합 친화력을 가진 적어도 2개의 합텐 ; 방사성 표지화, 또는 안정한 상자성 금속을 사용하여 표지화시키거나 또는 약품 또는 독소를 공유결합시키는데 적합한 적어도 1개의 부위, 및 이들 기능기를 공유결합시키는 화학적 구조로 되는 합성 분자로 되는 면역학적 시약.
  2. a) 2개의 상이한 접합체(여기서, 접합체는 각각 제1a)항에서와 같이 적합한 항원 및 합텐에 대하여 결합 친화력을 가짐)의 혼합물, b) 2개의 상이한 합텐(여기서, 합텐은 각각 제2a)항의 혼합물의 2개의 접합체 중 하나에 대하여 결합 친화력을 가짐) ; 방사성 표지화, 또는 안정한 상자성 금속을 사용하여 표지화시키거나 또는 약품 또는 독소를 공유 결합시키는데 적합한 적어도 1개의 부위 ; 및 이들 기능기를 공유 결합시키는 화학적 구조로 되는 합성 분자로 되는 면역학적 시약.
  3. 제1항에 있어서, 모노클로날 항체가 생쥐 항체인 시약.
  4. 제2항에 있어서, 모노클로날 항체가 생쥐 항체인 시약.
  5. 제3항에 있어서, 모노클로날 항체가 IgG 부류인 시약.
  6. 제4항에 있어서, 모노클로날 항체가 IgG 부류인 시약.
  7. 제5항에 있어서, 소편이 Fab'2또는 Fab' 또는 Fab인 시약.
  8. 제6항에 있어서, 소편이 Fab'2또는 Fab' 또는 Fab인 시약.
  9. 제1항에 있어서, 합텐이 2,4-디니트로페놀의 유도체인 시약.
  10. 제2항에 있어서, 합텐중 하나가 2,4-디니트로페놀의 유도체인 시약.
  11. 제1항 또는 제9항에 있어서, 생리학적 조건 하에서 접합체와 합텐 사이의 결합 작용의 해리 상수가 10-9-10-7M인 시약.
  12. 제2항 또는 제10항에 있어서, 생리학적 조건 하에서 접합체와 이 접합체에 대하여 특이적인 합텐 사이의 결합 작용의 해리 상수가 10-9-10-7M인 시약.
  13. 제1항에 있어서, 합성 분자에 금속 양이온으로 표지화시키는 데 적합한 킬레이트제가 함유된 시약.
  14. 제2항에 있어서, 합성 분자에 금속 양이온으로 표지화시키는 데 적합한 킬레이트제가 함유된 시약.
  15. 제9항 또는 제13항에 있어서, 합성 분자가 다음 구조식으로 표시되는 시약.
  16. 제2항에 있어서, 합성 분자에 할로겐으로 표지화시키는 데 적합한 페놀기가 함유된 시약.
  17. 제1항에 있어서, 합성 분자에 할로겐으로 표지화시키는 데 적합한 페놀기가 함유된 시약.
  18. 제2항에 있어서, 화합 결합 구조가 펩티드인 시약.
  19. 제1항에 있어서, 화합 결합 구조가 펩티드인 시약.
  20. 제9항, 제17항 또는 제19항에 있어서, 합성분자가 다음 구조식으로 표시되는 시약.
  21. 제19항에 있어서, 펩티드에 1개 또는 수개의 D-아미노산이 함유된 시약.
  22. 제18항에 있어서, 펩티드에 1개 또는 수개의 D-아미노산이 함유된 시약.
  23. 제1항에 있어서, 표지화된 부위가 합텐이고 그리하여, 제1a) 항의 접합체가 표지화된 합성 분자에 대하여 표지화되지 않은 부위보다 더 큰 결합 친화력을 가진 시약.
  24. 제2항에 있어서, 1개의 표지화된 부위가 2개의 합텐 중 1개 이고 그리고하여, 제2a) 항의 혼합물 중의 1개의 접합체가 표지화되지 않은 합텐 보다 표지화된 합텐에 대하여 더 큰 결합 친화력을 가진 시약.
  25. 제1항에 있어서, 적합한 항원이 종양과 관련된 항원인 시약.
  26. 제1항에 있어서, 적절한 항원이 세포와 관련된 항원인 시약.
  27. 제1항에 있어서, 적합한 항원이 조직과 관련된 항원인 시약.
  28. 제2항에 있어서, 1개의 적합한 항원이 종양과 관련된 항원이고 다른 1개의 항원이 종양, 세포 또는 조직과 관련된 항원인 시약.
  29. 제25항 또는 28항에 있어서, 종양이 흑종 또는 임파종, 또는 유방, 폐 또는 결장직장 종양인 시약.
  30. 제26항 또는 제28항에 있어서, 세포와 관련된 항원이 미오신 또는 빌린인 시약.
  31. 제27항 또는 제28항에 있어서, 조직과 관련된 항원이 피브린인 시약.
  32. 합성 분자를 표지화시킨후, 시약을 동시에 또는 계속적으로 주입시키고 형상을 선행 기술에 공지된 검출기를 사용하여 기록하는 것을 특징으로 하는 제1항 내지 31항 중 어느 하나의 항의 시약을 사용하여 생체내에서 목적 세포를 표적화시키는 방법.
  33. 제32항에 있어서, 합성 분자를 방사성이 측정된 적합한 방사성 동위원소로 표지화시키는 방법.
  34. 제33항에 있어서, 방사성 동위원소가18F,76Br,77Br,123I135I,131I,221At,57Co,67Ga,68Ga,67Cu,99Y,97Ru,99mTc,111In,203Pb 또는213Bi인 시약.
  35. 합성 분자를 상자성 금속 이온으로 표지화시킨 후, 시약을 동시에 또는 계속적으로 주입시키고 국재 부위에서의 증가된 자기 공명 완화를 적합한 MRI 장치에 의하여 검출하는 것을 특징으로 하는 제1항 내지 31항 중 어느 하나의 항의 시약을 사용하여 생체 내에서 목적세포를 표적화하는 방법.
  36. 제35항에 있어서, 상자성 금속이 Gd, Mn 또는 Fe인 방법.
  37. 합성 분자를 표지화시킨 후, 시약을 동시에 또는 계속적으로 주입시키고 이 시약을 표적 세포를 치사시키는 데 사용하는 것을 특징으로 하는 제1항 내지 31항 중 어느 하나의 항의 시약을 사용하여 생체내에서 목적 세포를 표적화시키는 방법.
  38. 제37항에 있어서, 합성분자를 방사성 동위원소로 표지화시키는 방법.
  39. 제38항에 있어서, 동위원소가131I,211At,99Y 또는212Bi인 방법.
  40. 1개 또는 수개의 세포독성 약품, 또는 1개 또는 수개의 세균성 또는 식물성 독소 분자를 합성 분자에 결합시킨 후, 시약을 동시에 또는 계속적으로 주입시키는 것을 특징으로 하는 제1항 내지 31항 중 어느 하나의 항의 시약을 사용하여 생체 내에서 목적 세포를 표적화하는 방법.
  41. 제40항에 있어서, 약품이 메토트렉세이트, 항 종양 빈카(Vinca) 알칼로이드 유도체, 백금 착물, 안트라시클린 또는 이들의 임의의 조합물질인 방법.
  42. 제41항에 있어서, 독소가 리신, 아브린, 겔로닌, 아메리카자리공 항비루스성 단백질, 디프테리아 독소 또는 이들의 임의의 조합 물질인 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019870010382A 1986-09-19 1987-09-18 특정 표적 세포의 검출 및 치사용 친화력 증강 면역학적 시약 KR900005622B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR86.13146 1986-09-19
FR8613146 1986-09-19
FR8613146A FR2604092B1 (fr) 1986-09-19 1986-09-19 Immunoreactifs destines a cibler les cellules animales pour leur visualisation ou leur destruction in vivo

Publications (2)

Publication Number Publication Date
KR880004312A true KR880004312A (ko) 1988-06-07
KR900005622B1 KR900005622B1 (ko) 1990-07-31

Family

ID=9339117

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019870010382A KR900005622B1 (ko) 1986-09-19 1987-09-18 특정 표적 세포의 검출 및 치사용 친화력 증강 면역학적 시약

Country Status (11)

Country Link
US (1) US5256395A (ko)
EP (1) EP0263046B1 (ko)
JP (1) JP2612454B2 (ko)
KR (1) KR900005622B1 (ko)
AT (1) ATE74769T1 (ko)
AU (1) AU613318B2 (ko)
CA (1) CA1306414C (ko)
DE (1) DE3778281D1 (ko)
ES (1) ES2032468T3 (ko)
FR (1) FR2604092B1 (ko)
GR (1) GR3004914T3 (ko)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6075010A (en) * 1992-06-09 2000-06-13 Neorx Corporation Small molecular weight ligand-hexose containing clearing agents
US6416738B1 (en) 1973-12-07 2002-07-09 Neorx Corporation Pretargeting methods and compounds
US5053226A (en) * 1987-07-15 1991-10-01 Board Of Regents, The University Of Texas System Monoclonal antibodies binding platinum complexes
AU609939B2 (en) * 1988-02-03 1991-05-09 University Of Melbourne, The Tumour imaging
CA1339775C (en) * 1988-06-10 1998-03-24 Shuzo Matsushita Antibody 0.5b to hiv-i gp 120 modified with toxic substance
US5439665A (en) * 1988-07-29 1995-08-08 Immunomedics Detection and treatment of infectious and inflammatory lesions
WO1990012109A1 (en) * 1989-03-30 1990-10-18 Board Of Regents, The University Of Texas System Monoclonal antibodies binding platinum complexes
FR2652004B1 (fr) * 1989-09-21 1994-10-28 Immunotech Partners Nouveaux derives hydrophiles, application au diagnostic et a la therapeutique, kits diagnostiques ou therapeutiques et reactifs immunologiques.
US5273743A (en) * 1990-03-09 1993-12-28 Hybritech Incorporated Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
US5684137A (en) * 1990-09-28 1997-11-04 Neorx Corporation S3 N chelating compounds for the radiolabeling of ligands, anti-ligands or other proteins
US6685930B1 (en) * 1991-03-27 2004-02-03 Tanox, Inc. Methods and substances for recruiting therapeutic agents to solid tumors
US5364612A (en) * 1991-05-06 1994-11-15 Immunomedics, Inc. Detection of cardiovascular lesions
US6096289A (en) 1992-05-06 2000-08-01 Immunomedics, Inc. Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy
US5541287A (en) * 1992-06-09 1996-07-30 Neorx Corporation Pretargeting methods and compounds
US5976535A (en) * 1992-06-09 1999-11-02 Neorx Corporation Pretargeting protocols for the enhanced localization of cytotoxins to target sites and cytotoxic combinations useful therefore
EP0646019B9 (en) * 1992-06-09 2002-12-18 Neorx Corporation Biotin-DOTA conjugates and their use in pretargeting methods
US5578287A (en) * 1992-06-09 1996-11-26 Neorx Corporation Three-step pretargeting methods using improved biotin-active agent
US5624896A (en) * 1992-06-09 1997-04-29 Neorx Corporation Clearing agents useful in pretargeting methods
US6217869B1 (en) 1992-06-09 2001-04-17 Neorx Corporation Pretargeting methods and compounds
US5911969A (en) 1992-06-09 1999-06-15 Neorx Corporation Pretargeting protocols for enhanced localization of active agents to target sites
US6358490B2 (en) 1992-06-09 2002-03-19 Neorx Corporation Three-step pretargeting methods and compounds
US6022966A (en) * 1993-11-22 2000-02-08 Neorx Corporation Pretargeting methods and compounds
US6228362B1 (en) 1992-08-21 2001-05-08 Immunomedics, Inc. Boron neutron capture therapy using pre-targeting methods
GB9300686D0 (en) * 1993-01-15 1993-03-03 Imp Cancer Res Tech Compounds for targeting
GB2300859B (en) * 1993-01-15 1997-06-18 Imp Cancer Res Tech Compounds comprising a target cell-specific portion and a further portion
EP0731797B1 (en) * 1993-12-03 1999-09-08 BRACCO S.p.A. Paramagnetic chelates for nuclear magnetic resonance diagnosis
US5561043A (en) * 1994-01-31 1996-10-01 Trustees Of Boston University Self-assembling multimeric nucleic acid constructs
US6908903B1 (en) 1994-12-07 2005-06-21 Aletheon Pharmaceuticals, Inc. Cluster clearing agents
US6172045B1 (en) 1994-12-07 2001-01-09 Neorx Corporation Cluster clearing agents
DE19500665A1 (de) * 1995-01-12 1996-07-18 Axel Prof Dr Haase Verfahren zur ortsauflösenden Abbildung eines Bereiches eines biologischen Objektes mit Hilfe elektromagnetischer Strahlen unter Applikation von Kontrastmittel
US5955605A (en) * 1995-02-21 1999-09-21 Neorx Corporation Biotinidase resistant biotin-DOTA conjugates
US6713045B1 (en) 1995-06-02 2004-03-30 Research Corporation Technologies, Inc. Targeted magnetic resonance imaging agents for the detection of physiological processes
US6770261B2 (en) 1995-06-02 2004-08-03 Research Corporation Technologies Magnetic resonance imaging agents for the detection of physiological agents
US7011812B1 (en) * 1996-05-03 2006-03-14 Immunomedics, Inc. Targeted combination immunotherapy of cancer and infectious diseases
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US5900228A (en) 1996-07-31 1999-05-04 California Institute Of Technology Bifunctional detection agents having a polymer covalently linked to an MRI agent and an optical dye
US6713046B1 (en) * 1997-10-27 2004-03-30 Research Corporation Technologies Magnetic resonance imaging agents for the delivery of therapeutic agents
CA2309749A1 (en) 1997-11-17 1999-05-27 Research Corporation Technologies, Inc. Magnetic resonance imaging agents for the detection of physiological agents
US20040166115A1 (en) * 2002-11-15 2004-08-26 Immunomedics, Inc. Use of multi-specific, non-covalent complexes for targeted delivery of therapeutics
ATE460946T1 (de) * 1998-06-22 2010-04-15 Immunomedics Inc Gebrauch von bispezifischen antikörpern in diagnose und therapie
US7387772B1 (en) 1999-06-22 2008-06-17 Immunimedics, Inc. Chimeric, human and humanized anti-CSAP monoclonal antibodies
US7052872B1 (en) 1999-06-22 2006-05-30 Immunomedics, Inc. Bi-specific antibodies for pre-targeting diagnosis and therapy
US7405320B2 (en) 1998-06-22 2008-07-29 Immunomedics, Inc. Therapeutic and diagnostic conjugates for use with multispecific antibodies
US6962702B2 (en) 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
US7833528B2 (en) * 1998-06-22 2010-11-16 Immunomedics, Inc. Use of multispecific, non-covalent complexes for targeted delivery of therapeutics
US7138103B2 (en) 1998-06-22 2006-11-21 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US6361774B1 (en) * 1999-09-17 2002-03-26 Immunomedics, Inc. Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug
US6576155B1 (en) * 1998-11-10 2003-06-10 Biocrystal, Ltd. Fluorescent ink compositions comprising functionalized fluorescent nanocrystals
US6673333B1 (en) 2000-05-04 2004-01-06 Research Corporation Technologies, Inc. Functional MRI agents for cancer imaging
ATE368477T1 (de) * 2000-06-20 2007-08-15 Immunomedics Inc Zielgerichtete kombinationsimmuntherapie für krebs und infektionskrankheiten
AU2001276956A1 (en) 2000-07-17 2002-01-30 California Institute Of Technology Macrocyclic mri contrast agents
WO2002028441A2 (en) 2000-10-04 2002-04-11 California Institute Of Technology Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits
US20030004236A1 (en) * 2001-04-20 2003-01-02 Meade Thomas J. Magnetic resonance imaging agents for detection and delivery of therapeutic agents and detection of physiological substances
US20030135108A1 (en) * 2001-05-02 2003-07-17 Silva Robin M. High throughput screening methods using magnetic resonance imaging agents
WO2002087632A1 (en) * 2001-05-02 2002-11-07 Metaprobe, Inc. High throughput screening methods using magnetic resonance imaging agents
DE60207733T2 (de) * 2001-07-30 2006-06-29 Smithkline Beecham Corp. Abbildung von transgenen markern
JP4443923B2 (ja) 2001-10-15 2010-03-31 イミューノメディクス、インコーポレイテッド 親和性向上剤
US7230085B2 (en) * 2001-11-28 2007-06-12 Immunomedics, Inc. Anti-DOTA antibody
US20030162709A1 (en) * 2001-12-26 2003-08-28 Edmund Rossi Methods of generating multispecific, multivalent agents from VH and VL domains
US7011816B2 (en) 2001-12-26 2006-03-14 Immunomedics, Inc. Labeling targeting agents with gallium-68 and gallium-67
AU2003209446B2 (en) * 2002-03-01 2008-09-25 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
EP2287201B1 (en) 2002-03-01 2018-12-12 Immunomedics, Inc. RS7 antibodies
US20030198597A1 (en) * 2002-04-22 2003-10-23 Meade Thomas J. Novel macrocyclic activatible magnetic resonance imaging contrast agents
EP1507562B1 (en) * 2002-05-29 2010-03-24 Immunomedics, Inc. Compositions for radioimmunotherapy of brain
US6911083B2 (en) * 2002-06-11 2005-06-28 Tokyo Institute Of Technology Method for producing powders made of gallium nitride and apparatus for producing the same
US7993626B2 (en) * 2007-01-11 2011-08-09 Immunomedics, Inc. Methods and compositions for F-18 labeling of proteins, peptides and other molecules
US7563433B2 (en) * 2007-01-11 2009-07-21 Immunomedics, Inc. Methods and compositions for F-18 labeling of proteins, peptides and other molecules
EP2301968A3 (en) 2002-06-14 2011-06-29 Immunomedics, Inc. Humanized monoclonal antibody HPAM4
US7597876B2 (en) * 2007-01-11 2009-10-06 Immunomedics, Inc. Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
US9701754B1 (en) 2002-10-23 2017-07-11 City Of Hope Covalent disulfide-linked diabodies and uses thereof
JP3931818B2 (ja) * 2003-02-13 2007-06-20 株式会社デンソー 車両用空調装置
CA2522819A1 (en) * 2003-04-22 2004-11-04 Immunomedics, Inc. Polyvalent protein complex
US7172751B2 (en) * 2003-06-13 2007-02-06 Immunomedics, Inc. D-amino acid peptides
US20050100543A1 (en) * 2003-07-01 2005-05-12 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
AU2004263538B2 (en) * 2003-08-08 2009-09-17 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
WO2005026325A2 (en) * 2003-09-10 2005-03-24 Surromed, Inc, Bivalent targeting of cell surfaces
EP1602928A1 (en) * 2004-06-01 2005-12-07 Universiteit Maastricht Process and kit for determining binding parameters of bioaffinity binding reactions
US7732131B2 (en) 2004-08-03 2010-06-08 Innate Pharma S.A. Therapeutic and diagnostic methods and compositions targeting 4Ig-B7-H3 and its counterpart NK cell receptor
DK2476705T3 (en) 2004-12-28 2015-12-14 Innate Pharma Monoclonal antibodies against NKG2A
DK3332808T3 (da) 2005-03-03 2020-12-14 Immunomedics Inc Humaniserede L243-antistoffer
EP1934260B1 (en) 2005-10-14 2017-05-17 Innate Pharma Compositions and methods for treating proliferative disorders
EP2674440B1 (en) 2005-12-16 2019-07-03 IBC Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
JP2009531324A (ja) 2006-03-20 2009-09-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 癌標的化のための操作された抗前立腺幹細胞抗原（ｐｓｃａ）抗体
US8709382B2 (en) 2007-01-11 2014-04-29 Immunomedics, Inc. Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
US8889100B2 (en) 2007-01-11 2014-11-18 Immunomedics, Inc. Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
US8398956B2 (en) 2007-01-11 2013-03-19 Immunomedics, Inc. In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
US8545809B2 (en) 2007-01-11 2013-10-01 Immunomedics, Inc. Methods and compositions for improved 18F labeling of proteins, peptides and other molecules
US8153100B2 (en) * 2007-01-11 2012-04-10 Immunomedics, Inc. Methods and compositions for F-18 labeling of proteins, peptides and other molecules
EP2197491A4 (en) 2007-09-04 2011-01-12 Univ California HIGHAFFINE ANTI-PROSTATE STEM CELL ANTIGEN (PSCA) ANTIBODIES TO CANCER AND TO THE DETECTION OF CANCER
JP5906090B2 (ja) 2009-02-17 2016-04-20 コーネル・リサーチ・ファンデーション・インコーポレイテッドＣｏｒｎｅｌｌ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ， Ｉｎｃｏｒｐｏｒａｔｅｄ 癌の診断のための方法およびキットならびに治療価の推定
IN2012DN01663A (ko) 2009-09-16 2015-06-05 Immunomedics Inc
EP2506881B1 (en) 2009-12-02 2024-03-06 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
JP6251477B2 (ja) 2009-12-02 2017-12-20 イマジナブ・インコーポレーテッド ヒト前立腺特異的膜抗原（ｐｓｍａ）をターゲッティングするｊ５９１ミニボディおよびｃｙｓダイアボディならびにこれらを使用するための方法
AU2010326004B2 (en) 2009-12-04 2016-04-21 Immunomedics, Inc. Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
WO2012151199A1 (en) 2011-05-02 2012-11-08 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
CN106029098A (zh) 2014-02-25 2016-10-12 免疫医疗公司 人源化rfb4抗cd22抗体
ES2892525T3 (es) 2014-10-07 2022-02-04 Immunomedics Inc Uso neoadyuvante de conjugados anticuerpo-fármaco
US11110303B2 (en) * 2014-11-26 2021-09-07 Baofa Yu Hapten-enhanced chemoimmunotherapy by ultra-minimum incision personalized intratumoral chemoimmunotherapy
AU2016252771B2 (en) 2015-04-22 2021-12-16 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells
KR102651537B1 (ko) 2015-05-20 2024-03-25 가고시마 유니버시티 IgG 결합 펩타이드에 의한 항체의 특이적 변형
EP3316885B1 (en) 2015-07-01 2021-06-23 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
WO2017027325A1 (en) 2015-08-07 2017-02-16 Imaginab, Inc. Antigen binding constructs to target molecules
WO2017189751A1 (en) 2016-04-26 2017-11-02 The University Of Utah Research Foundation Target-binding activated split reporter systems for analyte detection and related components and methods
CN109071606A (zh) * 2016-06-13 2018-12-21 国立大学法人鹿儿岛大学 利用IgG结合肽的位点特异性放射性同位素标记抗体
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3927193A (en) * 1973-05-18 1975-12-16 Hoffmann La Roche Localization of tumors by radiolabelled antibodies
US4401764A (en) * 1980-02-07 1983-08-30 Technicon Instruments Corporation Immunoassays employing labeled reagent and a conjugate having two binding sites
EP0035265B1 (en) * 1980-03-03 1986-01-02 Milton David Goldenberg Agent for tumor localization and therapy with labeled antibodies and antibody fragments
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
JPS579724A (en) * 1980-05-21 1982-01-19 Teijin Ltd Reactive polymer containing bonded cytotoxic substance and its preparation
US4714681A (en) * 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4433059A (en) * 1981-09-08 1984-02-21 Ortho Diagnostic Systems Inc. Double antibody conjugate
NL8204108A (nl) * 1981-10-27 1983-05-16 Hybritech Inc In beeld brengen van tumor met radioactief gemerkte monoclonale antilichamen.
US4445421A (en) * 1981-11-06 1984-05-01 The Charles Stark Draper Laboratory, Inc. Helicopter swashplate controller
US4444878A (en) * 1981-12-21 1984-04-24 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
ES8504461A1 (es) * 1982-04-12 1985-04-16 Hybritech Inc Un procedimiento para obtener un polidoma.
US4446233A (en) * 1982-05-05 1984-05-01 E. I. Du Pont De Nemours And Company Homogeneous immunoassay using covalent hybrid antibodies
US4470925A (en) * 1982-05-05 1984-09-11 E. I. Du Pont De Nemours And Company Immunoglobulin half-molecules and process for producing hybrid antibodies
US4472509A (en) * 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4454106A (en) * 1982-06-07 1984-06-12 Gansow Otto A Use of metal chelate conjugated monoclonal antibodies
US4741900A (en) * 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4490473A (en) * 1983-03-28 1984-12-25 Panab Labeled antibodies and methods
US4664911A (en) * 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
US4661444A (en) * 1984-03-29 1987-04-28 Ortho Diagnostic Systems Inc. Homogeneous immunoassays employing double antibody conjugates comprising anti-idiotype antibody
DE3583278D1 (de) * 1984-04-23 1991-07-25 Boston Biomed Res Inst Doppelspezifische antikoerper-determinanten.
US4722892A (en) * 1984-08-31 1988-02-02 Meares Claude F Monoclonal antibodies against metal chelates
GB8422452D0 (en) * 1984-09-05 1984-10-10 Serono Diagnostics Ltd Assay
US4760142A (en) * 1984-11-27 1988-07-26 Hoechst Celanese Corporation Divalent hapten derivatives
CA1282069C (en) * 1985-09-12 1991-03-26 Damon L. Meyer Antibody complexes of hapten-modified diagnostic or therapeutic agents
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4863713A (en) * 1986-06-23 1989-09-05 The Board Of Trustees Of Leland Stanford Jr. Univ. Method and system for administering therapeutic and diagnostic agents

Also Published As

Publication number Publication date
FR2604092A1 (fr) 1988-03-25
DE3778281D1 (de) 1992-05-21
AU7865687A (en) 1988-04-21
CA1306414C (en) 1992-08-18
KR900005622B1 (ko) 1990-07-31
GR3004914T3 (ko) 1993-04-28
JPS63159327A (ja) 1988-07-02
ES2032468T3 (es) 1993-02-16
JP2612454B2 (ja) 1997-05-21
EP0263046A1 (en) 1988-04-06
US5256395A (en) 1993-10-26
ATE74769T1 (de) 1992-05-15
AU613318B2 (en) 1991-08-01
EP0263046B1 (en) 1992-04-15
FR2604092B1 (fr) 1990-04-13

Similar Documents

Publication Publication Date Title
KR880004312A (ko) 특정 표적 세포의 검출 및 치사용 친화력 증강 면역학적 시약
Hnatowich et al. Investigations of avidin and biotin for imaging applications
Goodwin et al. Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens
US5274076A (en) Hydrophilic derivatives, their application to diagnosis and to therapeutics, diagnostic or therapeutic kits and immunological reagents
Rhodes et al. Technetium-99m labeling of murine monoclonal antibody fragments
US4895714A (en) Radioiodinated apotransferrin for use in tumor diagnosis, imaging, localization or treatment
Khawli et al. Effect of seven new vasoactive immunoconjugates on the enhancement of monoclonal antibody uptake in tumors
US4735210A (en) Lymphographic and organ imaging method and kit
US5807879A (en) Biotinidase-resistant biotinylated compound and methods of use thereof
Kupchik et al. Carcinoembryonic antigen (s) in liver disease: II. Isolation from human cirrhotic liver and serum and from normal liver
US5230883A (en) Method for localization and treatment of tumors using polylysine complexes
IL78993A (en) Antibodies and kit for use in radiotherapy and radioimmunoassay utilizing the same
JPS62500120A (ja) 金属キレ−トに対するモノクロ−ナル抗体
ES2201309T3 (es) Terapia por captura de neutrones de boro utilizando procedimientos de direccionamiento previo.
Paganelli et al. Pre-targeted immunodetection in glioma patients: tumour localization and single-photon emission tomography imaging of [99m Tc] PnAO-biotin
Searle et al. A human choriocarcinoma xenograft in nude mice, a model for the study of antibody localization
Fawwaz et al. Immunoreactivity and biodistribution of indium-111-labeled monoclonal antibody to a human high molecular weight-melanoma associated antigen
Kornguth et al. Magnetic resonance imaging of gadolinium-labeled monoclonal antibody polymers directed at human T lymphocytes implanted in canine brain
Hoffer et al. Tumor scanning agents
US3976763A (en) Chlorpromazine assay
Koizumi et al. Preparation of 67Ga-labeled antibodies using deferoxamine as a bifunctional chelate an improved method
Van den Abbeele et al. Antigen-binding site protection during radiolabeling leads to a higher immunoreactive fraction
RU98115277A (ru) Антитела с уменьшенным суммарным положительным зарядом
Hwang et al. Dynamic interaction of 111indium-labeled monoclonal antibodies with surface antigens of solid tumors visualized in vivo by external scintigraphy
Jalilian et al. Development of 111In-DTPA-human polyclonal antibody complex for long-term inflammation/infection detection

Legal Events

Date Code Title Description
A201 Request for examination
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
N231 Notification of change of applicant
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20020628

Year of fee payment: 13

LAPS Lapse due to unpaid annual fee